160 related articles for article (PubMed ID: 37431074)
1. [LEMS: Clinical Significance of Pathogenic Autoantibodies].
Motomura M; Irioka T
Brain Nerve; 2023 Jul; 75(7):837-845. PubMed ID: 37431074
[TBL] [Abstract][Full Text] [Related]
2. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Shiraishi H; Motomura M
Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
[TBL] [Abstract][Full Text] [Related]
3. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Yoshimura S; Shiraishi H; Motomura M
Brain Nerve; 2024 Jan; 76(1):33-40. PubMed ID: 38191137
[TBL] [Abstract][Full Text] [Related]
5. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
Sakai W; Nakane S; Matsuo H
Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
[TBL] [Abstract][Full Text] [Related]
6. [Lambert-Eaton myasthenic syndrome].
Motomura M; Fukuda T
Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
[TBL] [Abstract][Full Text] [Related]
7. [Paraneoplastic Cerebellar Degeneration with Lambert-Eaton Myasthenic Syndrome: A Report of an Effectively Treated Case and Systematic Review of Japanese Cases].
Kitanosono H; Motomura M; Tomita H; Iwanaga H; Iwanaga N; Irioka T; Shiraishi H; Tsujino A
Brain Nerve; 2019 Feb; 71(2):167-174. PubMed ID: 30718446
[TBL] [Abstract][Full Text] [Related]
8. [Lambert-Eaton Myasthenic Syndrome].
Matsuo H
Brain Nerve; 2024 May; 76(5):630-634. PubMed ID: 38741506
[TBL] [Abstract][Full Text] [Related]
9. [Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome].
Martin-Moutot N; de Haro L; Seagar M
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S28-34. PubMed ID: 15269657
[TBL] [Abstract][Full Text] [Related]
10. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
11. [Lambert-Eaton myasthenic syndrome (LEMS)].
Suzuki S
Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
[TBL] [Abstract][Full Text] [Related]
12. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
Hülsbrink R; Hashemolhosseini S
Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
[TBL] [Abstract][Full Text] [Related]
13. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.
Fukuda T; Motomura M; Nakao Y; Shiraishi H; Yoshimura T; Iwanaga K; Tsujihata M; Eguchi K
Ann Neurol; 2003 Jan; 53(1):21-8. PubMed ID: 12509844
[TBL] [Abstract][Full Text] [Related]
14. [Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with anti P/Q-type voltage-gated calcium channel antibody in a patient with primary double lung cancer].
Iwanami M; Odaka M; Nakamura T; Hirata K
Brain Nerve; 2009 Sep; 61(9):1083-7. PubMed ID: 19803409
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome Associated with Neuroendocrine Carcinoma of the Oropharynx.
Takasugi J; Shimamura M; Koda T; Kishikawa T; Hanamoto A; Inohara H; Sato K; Morii E; Motomura M; Sakaguchi M; Nakatsuji Y; Mochizuki H
Intern Med; 2018 Feb; 57(4):587-590. PubMed ID: 29093415
[TBL] [Abstract][Full Text] [Related]
16. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
[TBL] [Abstract][Full Text] [Related]
17. Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.
Ginebaugh SP; Badawi Y; Laghaei R; Mersky G; Wallace CJ; Tarr TB; Kaufhold C; Reddel S; Meriney SD
J Neurophysiol; 2023 May; 129(5):1259-1277. PubMed ID: 37073966
[TBL] [Abstract][Full Text] [Related]
18. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Titulaer MJ; Lang B; Verschuuren JJ
Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
[TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
20. [Seronegative nonparaneoplastic Lambert-Eaton myasthenic syndrome].
Sanadze AG; Sidnev DV; Tumurov DA
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):77-80. PubMed ID: 28638036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
